Literature DB >> 17495692

The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids.

David W Lee1, Ronald J Ozminkowski, Ginger Smith Carls, Shaohung Wang, Teresa B Gibson, Elizabeth A Stewart.   

Abstract

OBJECTIVE: To estimate direct medical costs and indirect (productivity related) for women age 25 to 54 who had clinically significant and symptomatic uterine fibroids (UF).
METHODS: We compared direct medical expenditures among 30,659 women who had clinically significant and symptomatic UF to expenditures among an equal number of matched controls who did not. We also compared indirect costs for a sub-sample of 910 employed women in each group. Regression analyses controlled for demographic and casemix factors.
RESULTS: Mean 12-month direct medical costs for women with UF were $11,720 versus $3257 for controls, and mean 12-month indirect costs for women with UF were $11,752 versus $8083 for controls. Differences were statistically significant (P<0.0001).
CONCLUSIONS: UF is a costly disorder and merits thought as interventions are considered to improve women's health and productivity.

Entities:  

Mesh:

Year:  2007        PMID: 17495692     DOI: 10.1097/JOM.0b013e31805f6cf2

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  21 in total

1.  Genome-wide analysis of loss of heterozygosity and copy number amplification in uterine leiomyomas using the 100K single nucleotide polymorphism array.

Authors:  Kellen L Meadows; Danica M K Andrews; Zongli Xu; Gleta K Carswell; Shannon K Laughlin; Donna D Baird; Jack A Taylor
Journal:  Exp Mol Pathol       Date:  2011-04-08       Impact factor: 3.362

2.  Characterization of tissue biomechanics and mechanical signaling in uterine leiomyoma.

Authors:  John M Norian; Carter M Owen; Juan Taboas; Casey Korecki; Rocky Tuan; Minnie Malik; William H Catherino; James H Segars
Journal:  Matrix Biol       Date:  2011-09-24       Impact factor: 11.583

Review 3.  The estimated annual cost of uterine leiomyomata in the United States.

Authors:  Eden R Cardozo; Andrew D Clark; Nicole K Banks; Melinda B Henne; Barbara J Stegmann; James H Segars
Journal:  Am J Obstet Gynecol       Date:  2011-12-11       Impact factor: 8.661

4.  Leiomyoma-related hospitalization and surgery: prevalence and predicted growth based on population trends.

Authors:  Mary Ellen Wechter; Elizabeth A Stewart; Evan R Myers; Rosanne M Kho; Jennifer M Wu
Journal:  Am J Obstet Gynecol       Date:  2011-07-20       Impact factor: 8.661

5.  Uterine artery embolization versus abdominal myomectomy: a long-term clinical outcome comparison.

Authors:  Anand Narayan; Adrea S Lee; George P Kuo; Neil Powe; Hyun S Kim
Journal:  J Vasc Interv Radiol       Date:  2010-05-31       Impact factor: 3.464

Review 6.  Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) Treatment of Symptomatic Uterine Fibroids: An Evidence-Based Analysis.

Authors:  G Pron
Journal:  Ont Health Technol Assess Ser       Date:  2015-03-01

7.  Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: An Economic Analysis.

Authors:  V Babashov; S Palimaka; G Blackhouse; D O'Reilly
Journal:  Ont Health Technol Assess Ser       Date:  2015-03-01

Review 8.  Uterine leiomyomas: individualizing the approach to a heterogeneous condition.

Authors:  Shannon K Laughlin; Elizabeth A Stewart
Journal:  Obstet Gynecol       Date:  2011-02       Impact factor: 7.661

9.  Cost-effectiveness of uterine-preserving procedures for the treatment of uterine fibroid symptoms in the USA.

Authors:  Anne H Cain-Nielsen; James P Moriarty; Elizabeth A Stewart; Bijan J Borah
Journal:  J Comp Eff Res       Date:  2014-05-30       Impact factor: 1.744

10.  The impact of uterine leiomyomas: a national survey of affected women.

Authors:  Bijan J Borah; Wanda K Nicholson; Linda Bradley; Elizabeth A Stewart
Journal:  Am J Obstet Gynecol       Date:  2013-07-24       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.